The UK market leader by revenue in the provision of teleradiology services
12-Mar-2018 – 157p – £174.4m – PER 20.5
Preliminary Results For The 12 Months To End December 2017 – Revenue up 18.2% to £33.7m, Gross profit margin of 48.7% (2016: 49.8%) as expected, Net Debt down significantly to £5m (2016: £22m), Proposed maiden final dividend of 1.10p, 1.65p for the year. Adjusted PBT is up 48.6% to £8.8m, £5.9m last time and Adjusted EPS is up 39.0% to 6.92p, 4.98 last time. 2018 has started well, trading in line with the Board’s expectations. Expects to grow Revenue at a double-digit rate similar to that seen in 2017.
Not looked at this before and it seems there was a mild profit warning in January. Following this, these results don’t appear too bad at all. Will keep an eye out here for updates as there seems to be decent Quality here and arguably based on that Quality, Value too (even though Stockopedia does not agree, Value Rank 14).
23-May-2018 – 133.4p – £148.2m – PER 16.4
AGM Statement – Started well, FY in-line with the Board’s expectations.
EPS forecast as +39% in 2018 and +14.1% the year after, ROCE and Operating Margin are great, there’s a small well covered Dividend and Debt is small. Not sure I am missing something here but this looks pretty good!
Subsequent note: I decided to buy in here.
25-Jul-2018 – 116p – £128.9m – PER 14.0
Trading Update For The 6 Months To End June 2018 – Recruitment momentum continued during H1 2018, FY to be in-line with market expectations.
I hold here and was getting a little nervous – Will see how the market reacts here, hopefully this will provide some support.
12-Sep-2018 – 145p – £161.1m – PER 17.2
Interim Results For The 6 Months To End June 2018 – Revenue up 18.2%, Adjusted Operating Profit up by 15.4% and Net Debt significantly reduced to £2.5m (2017: £8.5m). FY to be in-line.
I sold out here a couple of months or so ago as I was just getting a little nervous. This remains on my Watchlist because the forecasts if met, are quite impressive considering the current valuation.
Subsequent note: Gone Neutral here as more research indicated a 1 and 2 year downside here.